Acute Leukemias in Children with Down Syndrome

Pediatric Clinics of North America

Volumn 55, Issue 1, 2008, Pages 53-70

  Zwaan, Michel C ^a   Reinhardt, Dirk ^b   Hitzler, Johann ^c,d   Vyas, Paresh ^e  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTHRACYCLINE; ANTIINFECTIVE AGENT; BUSULFAN; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; GENOMIC DNA; JANUS KINASE 3; METHOTREXATE; MITOXANTRONE; RETINYLPALMITATE; TIOGUANINE; TRANSCRIPTION FACTOR GATA 1; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CLINICAL FEATURE; CLINICAL TRIAL; DOWN SYNDROME; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; EFFUSION; GENE EXPRESSION; GENE MUTATION; HEMATOLOGIC DISEASE; HUMAN; HYDROPS; LIVER FIBROSIS; MUCOSA INFLAMMATION; REMISSION; REVIEW; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; TRISOMY 21; WILD TYPE; WORLD HEALTH ORGANIZATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DOWN SYNDROME; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, MYELOID; MUTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 38649123691     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2007.11.001     Document Type: Review

References (83)

1. Greaves M. In utero origins of childhood leukaemia. Early Hum Dev 81 1 (2005) 123-129
2. Roizen N.J., and Patterson D. Down's syndrome. Lancet 361 9365 (2003) 1281-1289
3. Krivit W., and Good R.A. The simultaneous occurrence of leukemia and mongolism; report of four cases. AMA J Dis Child 91 3 (1956) 218-222
4. Hasle H., Clemmensen I.H., and Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 355 (2000) 165-169
5. Hitzler J.K., and Zipursky A. Origins of leukaemia in children with Down syndrome. Nat Rev Cancer 5 1 (2005) 11-20
6. Li Z., Godinho F.J., Klusmann J.H., et al. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet 37 6 (2005) 613-619
7. Massey G.V., Zipursky A., Chang M.N., et al. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): a Children's Oncology Group (COG) study POG-9481. Blood 107 (2006) 4606-4613
8. Al Kasim F., Doyle J.J., Massey G.V., et al. Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group Study. J Pediatr Hematol Oncol 24 1 (2002) 9-13
9. Vyas P., and Roberts I. Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis. Early Hum Dev 82 12 (2006) 767-773
10. Vyas P., and Crispino J.D. Molecular insights into Down syndrome-associated leukemia. Curr Opin Pediatr 19 1 (2007) 9-14
11. Whitlock J.A., Sather H.N., Gaynon P., et al. Clinical characteristics and outcome of children with down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 106 (2005) 4043-4049
12. Bassal M., La M.K., Whitlock J.A., et al. Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952. Pediatr Blood Cancer 44 (2005) 21-28
13. Creutzig U., Reinhardt D., Diekamp S., et al. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 19 8 (2005) 1355-1360
14. Gamis A.S., Woods W.G., Alonzo T.A., et al. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891. J Clin Oncol 21 18 (2003) 3415-3422
15. Tunstall-Pedoe O., De la Fuente J., and Bennet P.R. Trisomy 21 expands the megakaryocyte-erytroid progenitor compartment in human fetal liver-implications for Down syndrome AMKL. [abstract]. Blood 108 11 (2006) 170a
16. Henry E., Walker D., Wiedmeier S.E., et al. Hematological abnormalities during the first week of life among neonates with Down syndrome: data from a multihospital healthcare system. Am J Med Genet A 143 1 (2007) 42-50
17. Widness J.A., Pueschel S.M., Pezzullo J.C., et al. Elevated erythropoietin levels in cord blood of newborns with Down's syndrome. Biol Neonate 66 1 (1994) 50-55
18. Kivivuori S.M., Rajantie J., and Siimes M.A. Peripheral blood cell counts in infants with Down's syndrome. Clin Genet 49 1 (1996) 15-19
19. De Hingh Y.C., Van der Vossen P.W., Gemen E.F., et al. Intrinsic abnormalities of lymphocyte counts in children with Down syndrome. J Pediatr 147 6 (2005) 744-747
20. Weijerman ME, Van Furth AM, Vonk-Noordegraaf A, et al. Prevalence, neonatal characteristics and first year mortality of Down syndrome: a national study. J Pediatr, in press.
21. Pine S.R., Guo Q., Yin C., et al. Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. Blood 110 6 (2007) 2128-2131
22. Heald B., Hilden J.M., Zbuk K., et al. Severe TMD/AMKL with GATA1 mutation in a stillborn fetus with Down syndrome. Nat Clin Pract Oncol 4 7 (2007) 433-438
23. Muramatsu H., Watanabe N., Matsumoto K., et al. A retrospective analysis of 70 cases of transient leukemia in neonates with Down syndrome. [abstract]. Blood 108 11 (2006) 301b
24. Vardiman J.W., Harris N.L., and Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 7 (2002) 2292-2302
25. Hasle H., Niemeyer C.M., Chessells J.M., et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 17 2 (2003) 277-282
26. Creutzig U., Ritter J., Vormoor J., et al. Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group. Leukemia 10 11 (1996) 1677-1686
27. Lange B.J., Kobrinsky N., Barnard D.R., et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. Blood 91 2 (1998) 608-615
28. Gamis A.S., Alonzo T., Hiden J.M., et al. Outcome of Down syndrome children with acute myeloid leukemia (AML) or myelodysplasia (MDS) treated with a uniform prospective trial-initial report of the COG trial A2971. [abstract]. Blood 108 11 (2006) 9a
29. Zeller B., Gustafsson G., Forestier E., et al. Acute leukaemia in children with Down syndrome: a population-based Nordic study. Br J Haematol 128 6 (2005) 797-804
30. Gamis A.S. Acute myeloid leukemia and Down syndrome evolution of modern therapy-state of the art review. Pediatr Blood Cancer 44 1 (2005) 13-20
31. Ravindranath Y., Abella E., Krischer J.P., et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood 80 9 (1992) 2210-2214
32. Lie S.O., Jonmundsson G., Mellander L., et al. A population-based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: best outcome in girls, infants, and children with Down's syndrome. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Br J Haematol 94 1 (1996) 82-88
33. Ravindranath Y. Down syndrome and acute myeloid leukemia: the paradox of increased risk for leukemia and heightened sensitivity to chemotherapy. J Clin Oncol 21 18 (2003) 3385-3387
34. Creutzig U., Zimmermann M., Lehrnbecher T., et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol 24 27 (2006) 4499-4506
35. Zwaan C.M., Kaspers G.J.L., Pieters R., et al. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells, in children with and without Down syndrome. Blood 99 (2002) 245-251
36. Taub J.W., Stout M.L., Buck S.A., et al. Myeloblasts from Down syndrome children with acute myeloid leukemia have increased in vitro sensitivity to cytosine arabinoside and daunorubicin. Leukemia 11 9 (1997) 1594-1595
37. Frost B.M., Gustafsson G., Larsson R., et al. Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome?. [letter]. Leukemia 14 5 (2000) 943-944
38. Yamada S., Hongo T., Okada S., et al. Distinctive multidrug sensitivity and outcome of acute erythroblastic and megakaryoblastic leukemia in children with Down syndrome. Int J Hematol 74 4 (2001) 428-436
39. Taub J.W., and Ge Y. Down syndrome, drug metabolism and chromosome 21. Pediatr Blood Cancer 44 1 (2005) 33-39
40. Taub J.W., Matherly L.H., Stout M.L., et al. Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. Blood 87 8 (1996) 3395-3403
41. Taub J.W., Huang X., Matherly L.H., et al. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood 94 4 (1999) 1393-1400
42. Taub J.W., Huang X., Ge Y., et al. Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome. Cancer Res 60 22 (2000) 6421-6426
43. Ge Y., Jensen T.L., Stout M.L., et al. The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines. Cancer Res 64 2 (2004) 728-735
44. Al Ahmari A., Shah N., Sung L., et al. Long-term results of an ultra low-dose cytarabine-based regimen for the treatment of acute megakaryoblastic leukaemia in children with Down syndrome. Br J Haematol 133 6 (2006) 646-648
45. Abildgaard L., Ellebaek E., Gustafsson G., et al. Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature. Ann Hematol 85 5 (2006) 275-280
46. Hasle H, Niemeyer C, O'Marcaigh A, et al. Myeloid leukemia in children 4 years or older with Down syndrome. A BFM, DCOG, MRC, NOPHO collaborative study. [abstract]. Presented at the 5th Bi-annual Symposium on Childhood Leukemia. Noordwijkerhout, the Netherlands, April 30-May 2, 2006.
47. Pine S.R., Guo Q., Yin C., et al. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome. Leuk Res 29 11 (2005) 1353-1356
48. Hasle H., Lund B., Nyvold C.G., et al. WT1 gene expression in children with Down syndrome and transient myeloproliferative disorder. Leuk Res 30 5 (2006) 543-546
49. Dördelmann M., Schrappe M., Reiter A., et al. Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Münster Group. Leukemia 12 5 (1998) 645-651
50. Möricke A, Zimmermann M, Schwarz C, et al. Excellent event-free survival despite higher incidence of treatment related toxicity and mortality in Down syndrome patients with ALL as compared to patients without Down syndrome: data from the ALL-BFM 2000 trial [abstract]. Presented at the 5th Bi-annual Symposium on Childhood Leukemia. Noordwijkerhout, the Netherlands, April 30-May 2, 2006.
51. Pui C.H., Raimondi S.C., Borowitz M.J., et al. Immunophenotypes and karyotypes of leukemic cells in children with Down syndrome and acute lymphoblastic leukemia. J Clin Oncol 11 7 (1993) 1361-1367
52. Chessells J.M., Harrison C.J., Kempski H., et al. Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia Working Party. Leukemia 16 5 (2002) 776-784
53. Lanza C., Volpe G., Basso G., et al. The common TEL/AML1 rearrangement does not represent a frequent event in acute lymphoblastic leukaemia occuring in children with Down syndrome. Leukemia 11 6 (1997) 820-821
54. Steiner M., Attarbaschi A., Konig M., et al. Equal frequency of TEL/AML1 rearrangements in children with acute lymphoblastic leukemia with and without Down syndrome. Pediatr Hematol Oncol 22 3 (2005) 229-234
55. Garré M.L., Relling M.V., Kalwinsky D., et al. Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. J Pediatr 111 4 (1987) 606-612
56. Whitlock J.A. Down syndrome and acute lymphoblastic leukaemia. Br J Haematol 135 5 (2006) 595-602
57. Becton D., Dahl G.V., Ravindranath Y., et al. Randomized use of Cyclosporin A (CSA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group study 9421. Blood 107 (2006) 1315-1324
58. O'Brien M., Taub J., Stine K., et al. Excessive cardiotxocity despite excellent leukemia-free survival for pediatric patients with Down syndrome and acute myeloid leukemia: results from POG (Pediatric Oncology Group) protocol 9421. [abstract]. Blood 108 11 (2006) 168a-169a
59. Creutzig U., Diekamp S., Zimmermann M., et al. Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML. Pediatr Blood Cancer 48 7 (2007) 651-662
60. Cantor A.B. GATA transcription factors in hematologic disease. Int J Hematol 81 5 (2005) 378-384
61. Wechsler J., Greene M., McDevitt M.A., et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 32 1 (2002) 148-152
62. Kuhl C., Atzberger A., Iborra F., et al. GATA1-mediated megakaryocyte differentiation and growth control can be uncoupled and mapped to different domains in GATA1. Mol Cell Biol 25 19 (2005) 8592-8606
63. Muntean A.G., and Crispino J.D. Differential requirements for the activation domain and FOG-interaction surface of GATA-1 in megakaryocyte gene expression and development. Blood 106 4 (2005) 1223-1231
64. Hitzler J.K., Cheung J., Li Y., et al. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood 101 11 (2003) 4301-4304
65. Mundschau G., Gurbuxani S., Gamis A.S., et al. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood 101 11 (2003) 4298-4300
66. Rainis L., Bercovich D., Strehl S., et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood 102 (2003) 981-986
67. Groet J., McElwaine S., Spinelli M., et al. Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder. Lancet 361 9369 (2003) 1617-1620
68. Xu G., Nagano M., Kanezaki R., et al. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood 102 8 (2003) 2960-2968
69. Ahmed M., Sternberg A., Hall G., et al. Natural history of GATA1 mutations in Down syndrome. Blood 103 7 (2004) 2480-2489
70. Shimada A., Xu G., Toki T., et al. Fetal origin of the GATA1 mutation in identical twins with transient myeloproliferative disorder and acute megakaryoblastic leukemia accompanying Down syndrome. [letter]. Blood 103 1 (2004) 366
71. Taub J.W., Mundschau G., Ge Y., et al. Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome. Blood 104 5 (2004) 1588-1589
72. Deguchi K., and Gilliland D.G. Cooperativity between mutations in tyrosine kinases and in hematopoietic transcription factors in AML. Leukemia 16 4 (2002) 740-744
73. Hollanda L.M., Lima C.S., Cunha A.F., et al. An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis. Nat Genet 38 7 (2006) 807-812
74. De Vita S., Mulligan C., McElwaine S., et al. Loss-of-function JAK3 mutations in TMD and AMKL of Down syndrome. Br J Haematol 137 4 (2007) 337-341
75. Klusmann J.H., Reinhardt D., Hasle H., et al. Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down's syndrome. Leukemia 21 7 (2007) 1584-1587
76. Kiyoi H., Yamaji S., Kojima S., et al. JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults. Leukemia 21 3 (2007) 574-576
77. Walters D.K., Mercher T., Gu T.L., et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 10 1 (2006) 65-75
78. Norton A., Fisher C., Liu H., et al. Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome. Blood 110 3 (2007) 1077-1079
79. Mercher T., Wernig G., Moore S.A., et al. JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. Blood 108 8 (2006) 2770-2779
80. Bourquin J.P., Subramanian A., Langebrake C., et al. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci USA 103 (2006) 3339-3344
81. Marcucci G., Baldus C.D., Ruppert A.S., et al. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol 23 36 (2005) 9234-9242
82. Rainis L., Toki T., Pimanda J.E., et al. The proto-oncogene ERG in megakaryoblastic leukemias. Cancer Res 65 17 (2005) 7596-7602
83. Izraeli S., Rainis L., Hertzberg L., et al. Trisomy of chromosome 21 in leukemogenesis. Blood Cells Mol Dis 39 2 (2007) 156-159